Suppr超能文献

入院前使用抗抑郁药与膀胱癌:基于人群的队列研究,评估诊断时的分期、手术时间和手术结果。

Preadmission antidepressant use and bladder cancer: a population-based cohort study of stage at diagnosis, time to surgery, and surgical outcomes.

机构信息

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA and Regenstrief Institute, Inc, Indianapolis, IN, USA.

出版信息

BMC Cancer. 2018 Oct 24;18(1):1035. doi: 10.1186/s12885-018-4939-8.

Abstract

BACKGROUND

Among cancer patients, prior antidepressant use has been associated with impaired survival. This could be due to differences in stage at diagnosis, in receipt of treatment, or in treatment complications. The purpose of this study was, therefore, to examine if preadmission antidepressant use in patients with bladder cancer is associated with tumor stage at diagnosis, rate of cystectomy, and surgical outcomes, including survival.

METHODS

We performed a registry-based cohort study including all patients with incident invasive bladder cancer in Denmark 2005-2015. Exposure was defined as redemption of two or more antidepressant prescriptions one year before cancer diagnosis. We compared tumor stage using logistic regression, postsurgical inpatient length of stay using linear regression, and other outcomes using Cox regression. All results were adjusted for age, sex, comorbidity, and marital status.

RESULTS

Among 10,427 bladder cancer patients, 10% were antidepressant users. At diagnosis, 51% of users and 52% of non-users had muscle-invasive disease. However, upon adjustment for age, sex, comorbidity, and marital status, users had lower odds of muscle-invasive disease (adjusted odds ratio 0.86 (95% confidence interval (CI) 0.74-0.99)). Among patients with muscle-invasive disease, fewer users than non-users had surgery within three months (15% vs. 24%, adjusted hazard ratio (aHR) 0.75 (95% CI 0.59-0.95)). Of 2532 patients undergoing surgery, 6% were antidepressant users. Postsurgical inpatient length of stay did not differ between users and non-users. The 30-day cumulative incidence of readmission was higher for users (41% vs. 33%, aHR 1.33 (95% CI 1.05-1.67)), while the 90-day incidence of postoperative procedures was 44% for users and 38% for non-users (aHR 1.18 (95% CI 0.93-1.51)). One-year mortality was comparable in users (15%) and non-users (14%).

CONCLUSIONS

Antidepressant use in bladder cancer patients was associated with less advanced stage at diagnosis and lower rate of cystectomy. After cystectomy, users had higher rate of readmission and postoperative procedures than non-users, but we found no difference in length of stay or one-year mortality. The results point to the importance of differentiated clinical care according to individual patient characteristics.

摘要

背景

在癌症患者中,既往使用抗抑郁药与生存预后不良相关。这可能是由于诊断时的分期、治疗的实施以及治疗相关并发症的差异导致的。因此,本研究旨在探究膀胱癌患者入院前使用抗抑郁药是否与诊断时的肿瘤分期、行膀胱切除术的比例以及包括生存预后在内的手术结局相关。

方法

我们开展了一项基于丹麦全国注册登记处的队列研究,纳入了 2005 年至 2015 年间所有诊断为侵袭性膀胱癌的患者。暴露因素定义为在癌症诊断前一年至少使用了 2 种以上的抗抑郁药物。我们使用 logistic 回归比较肿瘤分期,使用线性回归比较术后住院时间,使用 Cox 回归比较其他结局。所有结果均经过年龄、性别、合并症和婚姻状况的校正。

结果

在 10427 例膀胱癌患者中,10%的患者使用了抗抑郁药。诊断时,51%的使用者和 52%的非使用者存在肌层浸润性疾病。然而,经过年龄、性别、合并症和婚姻状况的校正后,使用者发生肌层浸润性疾病的可能性更低(校正比值比 0.86(95%置信区间 0.74-0.99))。在存在肌层浸润性疾病的患者中,与非使用者相比,使用者在三个月内行手术的比例更低(15%比 24%,校正危险比 0.75(95%置信区间 0.59-0.95))。在接受手术的 2532 例患者中,6%的患者使用了抗抑郁药。使用者和非使用者的术后住院时间没有差异。使用者的 30 天累积再入院率更高(41%比 33%,校正危险比 1.33(95%置信区间 1.05-1.67)),而 90 天的术后治疗比例为 44%的使用者和 38%的非使用者(校正危险比 1.18(95%置信区间 0.93-1.51))。使用者(15%)和非使用者(14%)的一年死亡率相当。

结论

膀胱癌患者入院前使用抗抑郁药与诊断时的肿瘤分期较低以及膀胱切除术实施比例较低相关。在接受膀胱切除术后,与非使用者相比,使用者的再入院率和术后治疗比例更高,但我们未发现住院时间或一年死亡率的差异。这些结果提示,应根据患者的个体特征进行差异化的临床护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/245b/6201496/609cc622c238/12885_2018_4939_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验